<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03427853</url>
  </required_header>
  <id_info>
    <org_study_id>LY06006</org_study_id>
    <nct_id>NCT03427853</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Denosumab in Healthy Adults</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group, Placebo-controlled, Single-dose Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Denosumab Injection Administered Subcutaneously to Healthy Adults in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Boan Biotechnology Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, parallel-group, placebo-controlled, single-dose&#xD;
      escalation Phase I study to evaluate the safety, tolerability, pharmacokinetics,&#xD;
      pharmacodynamics and immunogenicity of denosumab injection administered subcutaneously to&#xD;
      healthy adults in China&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, parallel-group, placebo-controlled, single-dose&#xD;
      escalation Phase I study in healthy adults in China, conducted in one center.&#xD;
&#xD;
      The objectives are to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics&#xD;
      and immunogenicity of denosumab injection (code name:LY06006).&#xD;
&#xD;
      Subjects would be sequentially enrolled in one of three cohorts. Eight subjects in the first&#xD;
      cohort would receive a single 18 mg subcutaneous injection of LY06006. If the safety and&#xD;
      tolerability were confirmed at Day 56, the other 16 subjects would be enrolled in the second&#xD;
      cohort to receive a single 60 mg subcutaneous injection of LY06006. If the safety and&#xD;
      tolerability were confirmed at Day 56 in 60-mg group, the last 8 subjects would be enrolled&#xD;
      in the third cohort to receive a single 120 mg subcutaneous injection of LY06006.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Anticipated">December 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double-blind, parallel-group, placebo-controlled, single-dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind,</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment related adverse events</measure>
    <time_frame>56 days</time_frame>
    <description>Number of patients with treatment related adverse events assessed by change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal laboratory values</measure>
    <time_frame>56 days</time_frame>
    <description>Number of patients with abnormal laboratory values assessed by change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Curve (AUC)</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with anti drug antibodies</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>LY06006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY06006 18mg, 60mg 120mg subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY06006</intervention_name>
    <description>LY06006 18mg, 60mg, 120mg subcutaneous injection</description>
    <arm_group_label>LY06006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed ICF and complied with ICF requirement and restrictions&#xD;
&#xD;
          -  Healthy male and female, 18≤age≤65&#xD;
&#xD;
          -  In screening visit, male body weight≥50kg，female body weight≥45kg，and 19.0≤BMI≤24.0&#xD;
             kg/m2；&#xD;
&#xD;
          -  At screening visit: physical examination, vital signs, laboratory tests,&#xD;
             electrocardiogram, chest X-ray examination, abdominal CT examination are normal or&#xD;
             abnormal but no clinical significance confirmed by investigators；&#xD;
&#xD;
          -  During the study period and within 12 months after the study drug administration, the&#xD;
             subjects and partners agreed to use reliable contraceptive measures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women；&#xD;
&#xD;
          -  Fertility plan within one year；&#xD;
&#xD;
          -  The subject has a history of hypersensitivity or allergy to LY06006 or any of its&#xD;
             excipients；or allergy to any drug, food and pollen, or IGE test is positive.&#xD;
&#xD;
          -  Subjects are suffering from or have had osteomyelitis or osteonecrosis of the Jaw, or&#xD;
             plan to have invasive dental or maxillofacial surgery during the study, or dental or&#xD;
             oral surgery wounds unhealed;&#xD;
&#xD;
          -  Have fractures in past six months；&#xD;
&#xD;
          -  Active respiratory, digestive, urinary, reproductive or skin infections；&#xD;
&#xD;
          -  Have oncology family history ；&#xD;
&#xD;
          -  Have mental illness history；&#xD;
&#xD;
          -  In screening visit: Chest X-ray, abdominal CT indicated clinical significance，for&#xD;
             example: tuberculosis, inflammation, et al；&#xD;
&#xD;
          -  PPD test positive with 48-72 hrs induration reading≥5mm；&#xD;
&#xD;
          -  Blood chemistry：ALT or AST &gt;1.5 ULN，Cr&gt;1.0 ULN；Blood routine：WBC&lt;0.8 LLN or&gt;1.2&#xD;
             ULN；NE&lt;0.8 LLN；PLT&lt;0.8 LLN；HGB&lt;0.8LLN；&#xD;
&#xD;
          -  Suffering from or have had the following diseases affecting the bone metabolism:&#xD;
             malignant tumors (including myeloma), hypoparathyroidism / hyperthyroidism,&#xD;
             hypothyroidism, acromegaly, cushing's syndrome, hypopituitarism, severe chronic&#xD;
             obstructive pulmonary disease, rheumatoid arthritis, osteomalacia et al;&#xD;
&#xD;
          -  The medicines that may affect bone turnover are used before randomization or planned&#xD;
             to use in the study period , including but not limited : denosumab, bisphosphonates or&#xD;
             fluorides were used in past 12 months; contraceptives with hormone，hormone replacement&#xD;
             therapy（tibolone、hormone、selective estrogen receptor modulators）aromatase inhibitors,&#xD;
             calcitonin, strontium salt, parathyroid hormone (or derivative), vitamin D&#xD;
             supplement，anabolic steroids, systemic glucocorticoids, calcitriol or analogues,&#xD;
             diuretics, anticonvulsant drugs；inhalation or local use of glucocorticoids within 2&#xD;
             weeks&#xD;
&#xD;
          -  Significant changes in physical activity in 6 months before randomization; or have&#xD;
             been playing strenuous sports, or plan to play strenuous sports during the study&#xD;
             period.&#xD;
&#xD;
          -  Any of HBsAg, HCV-Ab, Anti-HIV, TP-Ab is positive；&#xD;
&#xD;
          -  Hypocalcemia or hypercalcemia，or serum calcium calibrated by serum albumin is not&#xD;
             within the normal range&#xD;
&#xD;
          -  The average daily smoking amount is more than 5 cigarettes per day during three months&#xD;
             before randomization, or smoking can't be prohibited during the study period;&#xD;
&#xD;
          -  Alcohol abuse or drank more than 28 units / week of alcohol((1 unit =350ml beer, 45ml&#xD;
             spirits or 150ml Wine), or alcohol breath test is positive；&#xD;
&#xD;
          -  History of drug dependency or drug abuse, or urine drug screening test is positive；&#xD;
&#xD;
          -  Donated whole blood, blood component, or massive hemorrhage （&gt;400ml）three months&#xD;
             before randomization.&#xD;
&#xD;
          -  Use of any vaccines in 6 months of initiation of study therapy&#xD;
&#xD;
          -  participation in another clinical trial within 3 months prior to enrollment&#xD;
&#xD;
          -  Had Blood faint and acupuncture syncope history；&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huanhuan Jiang</last_name>
    <role>Study Director</role>
    <affiliation>Shangdon Boan Biotechnology Co Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Fang, MD</last_name>
    <phone>8610-8832666</phone>
    <email>fygk7000@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Xicheng District</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Fang</last_name>
      <phone>8610-88326666</phone>
      <email>fygk7000@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

